Peptide LibraryRelamorelin dosage in published studies and labels
These are the doses used for Relamorelin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Relamorelin has no approved dosage. Human dosing comes from trials in diabetic gastroparesis: the phase 2b trial gave 10, 30 or 100 mcg injected under the skin twice a day for 12 weeks and reduced core symptoms against placebo, and phase 3 trials used 10 mcg twice a day. The phase 3 programme was terminated, which the registry attributes solely to a business decision.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 10–100 mcg twice daily in phase 2 trials; 10 mcg twice daily in phase 3 |
| Route | Subcutaneous |
| Frequency | Twice daily |
| Duration studied | 35 days to 12 weeks in the gastroparesis trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2b, diabetic gastroparesis (NCT02357420)Clinical trial · Randomized, placebo-controlled phase 2b trial | Adults with diabetes and moderate to severe gastroparesis symptoms (n=393) | 10, 30 or 100 mcg | Subcutaneous | Twice daily | 12 weeks, after a 2-week placebo run-in | Core symptoms and composite score fell versus placebo at all doses; gastric emptying faster; vomiting frequency not significantly different from placebo; worse glucose control in 14.5% | Efficacy and Safety of Relamorelin in Diabetics With Symptoms of Gastroparesis: A Randomized, Placebo-Controlled Study. Gastroenterology. 2017. |
| Phase 3, diabetic gastroparesis — terminated (NCT03285308)Clinical trial · Phase 3 randomized, placebo-controlled trial, terminated | Adults with diabetic gastroparesis (n=336) | 10 mcg | Subcutaneous | Twice daily | Up to 12 weeks, after a 2-week placebo run-in | Terminated; the registry reason is that the relamorelin programme was being terminated solely based on a business decision. Results are posted on ClinicalTrials.gov and not summarised here | NCT03285308 — A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01 |
| Phase 2, diabetic gastroparesis (NCT01571297)Clinical trial · Phase 2 double-blind, placebo-controlled trial | Adults with diabetic gastroparesis (n=204) | Various doses and regimens from 10 to 100 mcg | Subcutaneous | Per trial protocol | 35 days | Gastric emptying time (primary outcome); results not posted on ClinicalTrials.gov | NCT01571297 — Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis |
| MOVE-PD — constipation in Parkinson's diseaseClinical trial · Randomized, double-blind, placebo-controlled trial | People with Parkinson's disease and chronic constipation (18 of an intended 56 completed) | Not stated in the indexed abstract | Not stated in the indexed abstract | Not stated in the indexed abstract | Not stated in the indexed abstract | Recruitment goals were not met, so no benefit could be shown | A randomized trial of relamorelin for constipation in Parkinson's disease (MOVE-PD): Trial results and lessons learned. Parkinsonism Relat Disord. 2017. |
Where sources disagree
- The phase 3 gastroparesis programme was terminated. ClinicalTrials.gov gives the reason as a business decision; the registry does not describe it as a safety decision.
- Relamorelin is a ghrelin agonist studied for gut motility. Its microgram doses come from gastroparesis trials and say nothing about its use for growth hormone or appetite.
- Dose-related worsening of blood sugar control was reported in the phase 2b trial, and some participants needed changes to their diabetes medicines.